Fifth Third Bancorp: Q2 Earnings Insights

  Fifth Third Bancorp (NASDAQ:FITB) reported its Q2 earnings results on Thursday, July 21, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

 

Fifth Third Bancorp (NASDAQ:FITB) reported its Q2 earnings results on Thursday, July 21, 2022 at 06:30 AM.

Here’s what investors need to know about the announcement.

Earnings

Fifth Third Bancorp missed estimated earnings by 13.64%, reporting an EPS of $0.76 versus an estimate of $0.88.

Revenue was up $66.00 million from the same period last year.

Past Earnings Performance

Last quarter the company missed on EPS by $0.01 which was followed by a 0.29% drop in the share price the next day.

Here’s a look at Fifth Third Bancorp’s past performance:

 

Quarter Q1 2022 Q4 2021 Q3 2021 Q2 2021
EPS Estimate 0.69 0.9 0.91 0.80
EPS Actual 0.68 0.9 0.97 0.94
Revenue Estimate 1.94B 2.02B 1.98B 1.94B
Revenue Actual 1.88B 1.99B 2.03B 1.95B

To track all earnings releases for Fifth Third Bancorp visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Elicio Therapeutics Presents Updated Preliminary Immunogenicity Data From The Ongoing Phase 1 Study Of ELI-002 And New Preclinical Data On ELI-007 And ELI-008 At The Society For Immunotherapy Of Cancer Annual Meeting

In patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers who were given ELI-002 2P, an investigational therapeutic cancer vaccine, as monotherapy, 87% (20/23) had direct ex vivo mKRAS-specific T

ELTX